Nutromics’ drug monitoring patch secures FDA breakthrough designation
September 11, 2026
Breakthrough designation for Nutromics’ namesake patch applies to the wearable platform’s function in vancomycin drug monitoring.
Breakthrough designation for Nutromics’ namesake patch applies to the wearable platform’s function in vancomycin drug monitoring.
Pelvic organ prolapse is a common but often overlooked condition that affects millions of women. It occurs when the tissues that support the pelvic organs weaken, allowing organs such as the bladder, uterus or rectum to shift from their normal position. Doctors can assess how severe the prolapse is, but existing tools do not provide much information about what’s happening inside the tissue itself.
UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, Phase I clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become cancer-free.
Adelaide University researchers have developed a new way to use mRNA technology to reprogram tumor-supporting immune cells and strengthen the body’s anticancer immune response.
Columbia University researchers have identified a way to help predict when people at high risk of developing Alzheimer’s are likely to develop their first symptoms, a finding that could help physicians decide when to prescribe preventive treatments currently in development.
IceCure Medical Ltd. announced that it has received approval, as a Class III medical device, from China’s National Medical Products Administration (“NMPA”) for its ProSense® system and associated cryoprobes.
GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”, or “the company”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity. Alongside the clearance, the company also announced the product’s full commercial launch.
Drawing on research pioneered at Tufts, Anodyne Nanotech is creating patches that could change the future of medicine
The FDA’s decision follows a clinical assessment of the Emboliner, including the PROTECT H2H IDE study.
Johnson & Johnson MedTech (NYSE: JNJ) announced today that it has received a CE mark for its Acuvue Oasys Max 2-Week, a new reusable contact lens.